At Flatiron, we are unlocking HEOR evidence and insights to demonstrate the value of oncology treatments to stakeholders including payers, regulators, and providers. By leveraging our industry leading multinational oncology data assets and expertise, we’re generating a spectrum of tailored solutions configured for the specific evidence needs of life sciences companies.

Our research explores methodological approaches and considerations for health outcomes research, use of AI and large language models to advance evidence generation, among other topics.

With an ever-increasing number of treatment options, assessing the impact of changing treatment sequences/pathways has become crucial in health technology assessment (HTA). A major challenge is the scarcity of clinical effectiveness evidence, as trials typically do not compare treatment sequences. Real-world data (RWD) offers an alternative for capturing evidence on treatment sequences but analyses require appropriate statistical methods/assumptions to address time-varying confounding and immortal time bias. Descriptive treatment pattern analyses (e.g. Sankey diagrams) are useful but do not answer the counterfactual (i.e., what-if) questions required for HTA, particularly what would have happened had patients received alternative treatment sequences and the attributable effect of different lines of treatment (LOTs).

This workshop provides an in-depth discussion on recent advances in treatment sequence evaluation in HTA, with tutorials on advanced methods for comparing treatment sequences using RWD.

Health Technology Assessment (HTA) bodies increasingly consider supplementary evidence from real-world data (RWD) alongside traditional data sources like RCTs. However there remain concerns about bias and the applicability of RWD from other countries to the local settings, further complicated by the uneven availability of high-quality RWD across different geographical regions. This workshop will discuss how transportability analysis, like methods used to adjust for confounding factors, can help bridge this gap. Recently NICE updated their real-world evidence framework to include transportability methods as a potential approach to adjust for external validity concerns.

Unlocking the power of real-world data across the globe: Recent research accomplishments from Flatiron FORUM and multinational data

— Flatiron FORUM

As we continue to push the boundaries of what’s possible with real-world data (RWD), I’m excited to share some of the latest research accomplishments from Flatiron Health’s FORUM and our international data initiatives. These efforts are not only advancing the field of oncology but also reshaping how we think about health technology assessments (HTAs) and global evidence generation. Here’s a glimpse into why these findings are novel and how they’re making an impact.

In this study, researchers evaluated the transportability of overall survival estimates from the US to the UK for metastatic breast cancer (mBC) using the US Flatiron Health EHR-derived database and the UK National Cancer Registration and Analysis Service cancer registry. This research validates transportability as a methodology for using data across borders, with the potential to improve standards of care, speed to access treatments, and provide more confidence in how medicines perform.

Flatiron Health at ISPOR EU 2024

Unlock critical evidence to accelerate access to cancer treatments worldwide

Featured sessions

Workshop: Advanced Methods for Comparing Treatment Sequences or Pathways

discussion leader

panelists

Issue Panel: From Data to Decisions - The Potential of RWE Transportability in Healthcare Decision Making

discussion leader

panelists

Featured solutions

Accelerate market access with Flatiron’s RWE and HTA expertise

Filling critical evidence generation gaps with global oncology real-world data

Featured content

Unlocking the power of real-world data across the globe: Recent research accomplishments from Flatiron FORUM and multinational data

— Flatiron FORUM

Flatiron experts at ISPOR EU

Our research

Transportability of overall survival estimates from the US to England in metastatic breast cancer using nationally representative data sources

See this research

Connect with a flatiron expert

Development of oncology EHR-derived real-world data in Europe and Japan

See this research

Connect with a flatiron expert

Real-world data sources for oncology in five major European countries: a targeted literature review

See this research

Connect with a flatiron expert

Transporting real-world evidence: Is it possible to transport OS estimates in HER2+ mBC from US to UK

See this research

Connect with a flatiron expert

Is individual-patient data essential for transportability, or can aggregated data suffice?

See this research

Connect with a flatiron expert

Looking for support in designing and executing HEOR studies with RWE?

Request a meeting